A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET) Meeting Abstract
| Authors: | Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Kundamal, N.; Liao, S.; Ji, Y.; Crystal, A.; Curigliano, G. |
| Abstract Title: | A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET) |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012503333 |
| DOI: | 10.1158/1538-7445.Sabcs19-pd7-09 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PD7-09 -- Source: Wos |
